267 related articles for article (PubMed ID: 22389731)
1. Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.
Messer WB; Yount B; Hacker KE; Donaldson EF; Huynh JP; de Silva AM; Baric RS
PLoS Negl Trop Dis; 2012; 6(2):e1486. PubMed ID: 22389731
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
[TBL] [Abstract][Full Text] [Related]
3. Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common marmosets (Callithrix jacchus).
Azami NAM; Moi ML; Ami Y; Suzaki Y; Lim CK; Taniguchi S; Saijo M; Takasaki T; Kurane I
Virol J; 2018 Mar; 15(1):51. PubMed ID: 29587780
[TBL] [Abstract][Full Text] [Related]
4. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
VanBlargan LA; Milutinovic PS; Goo L; DeMaso CR; Durbin AP; Whitehead SS; Pierson TC; Dowd KA
J Virol; 2021 Nov; 95(23):e0095621. PubMed ID: 34549976
[TBL] [Abstract][Full Text] [Related]
5. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
[TBL] [Abstract][Full Text] [Related]
6. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
7. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
Messer WB; de Alwis R; Yount BL; Royal SR; Huynh JP; Smith SA; Crowe JE; Doranz BJ; Kahle KM; Pfaff JM; White LJ; Sariol CA; de Silva AM; Baric RS
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1939-44. PubMed ID: 24385585
[TBL] [Abstract][Full Text] [Related]
8. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
[TBL] [Abstract][Full Text] [Related]
9. Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunity.
Chen RE; Smith BK; Errico JM; Gordon DN; Winkler ES; VanBlargan LA; Desai C; Handley SA; Dowd KA; Amaro-Carambot E; Cardosa MJ; Sariol CA; Kallas EG; Sékaly RP; Vasilakis N; Fremont DH; Whitehead SS; Pierson TC; Diamond MS
Cell Host Microbe; 2021 Nov; 29(11):1634-1648.e5. PubMed ID: 34610295
[TBL] [Abstract][Full Text] [Related]
10. Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
Dowd KA; DeMaso CR; Pierson TC
mBio; 2015 Nov; 6(6):e01559-15. PubMed ID: 26530385
[TBL] [Abstract][Full Text] [Related]
11. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
[TBL] [Abstract][Full Text] [Related]
12. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
Galula JU; Shen WF; Chuang ST; Chang GJ; Chao DY
J Virol; 2014 Sep; 88(18):10813-30. PubMed ID: 25008922
[TBL] [Abstract][Full Text] [Related]
13. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
[TBL] [Abstract][Full Text] [Related]
14. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
Brien JD; Austin SK; Sukupolvi-Petty S; O'Brien KM; Johnson S; Fremont DH; Diamond MS
J Virol; 2010 Oct; 84(20):10630-43. PubMed ID: 20702644
[TBL] [Abstract][Full Text] [Related]
15. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
[TBL] [Abstract][Full Text] [Related]
17. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
[TBL] [Abstract][Full Text] [Related]
18. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
[TBL] [Abstract][Full Text] [Related]
19. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
[TBL] [Abstract][Full Text] [Related]
20. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
